RxDoctor Payments Data

Richard Monk, MD

Pulmonary Disease · West Columbia, SCNPI 1811150352

Payments from drug & device makers

$2,083in general payments, 2019–2025

Across 134 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Electromed, Inc.$215
  • Sunovion Pharmaceuticals Inc.$194
  • Sanofi$90
  • Resmed Corp$67
  • Actelion Pharmaceuticals US, Inc.$62
  • plus $347 from 12 others

What the payments were for

  • Food & beverage$2,04898%
  • Entertainment$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,083 in reported general payments places this provider in the 40th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$230,090
Medicare patients
1,098
Services billed
2,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate49$651,230
Trelegy ElliptaFluticasone/Umeclidin/Vilanter465$474,550
OpsumitMacitentan29$368,714
Spiriva RespimatTiotropium Bromide287$226,883
Stiolto RespimatTiotropium Br/Olodaterol Hcl223$169,669
Breo ElliptaFluticasone/Vilanterol291$161,322
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr137$104,400
Breztri AerosphereBudesonide/Glycopyr/Formoterol110$91,569
Incruse ElliptaUmeclidinium Bromide92$47,672
Dupixent PenDupilumab12$44,239
SymbicortBudesonide/Formoterol Fumarate106$38,305
Arnuity ElliptaFluticasone Furoate73$28,713
Wixela InhubFluticasone Propion/Salmeterol109$22,537
Advair HfaFluticasone Propion/Salmeterol50$20,433
Fluticasone-SalmeterolFluticasone Propion/Salmeterol100$19,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,107$816,6581,058 claims
Actelion Pharmaceuticals US, Inc.Opsumit$62$368,71429 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$30$142,785237 claims
MerckDulera$26$12,66827 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$14$4,03716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →